Jardiance effectiveness in Chinese heart failure patients
Treatments studied
Part of Heart & circulation clinical trials.
This trial is looking at how well Jardiance (a medication for heart failure) works in Chinese patients with a specific type of heart failure called heart failure with reduced ejection fraction. It compares Jardiance to other standard heart failure medications to see which is more effective and safe.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have been diagnosed with heart failure with reduced ejection fraction (a type of heart failure where the heart doesn't pump blood well).
- Your ejection fraction (a measure of heart pumping strength) is 40% or less.
- You have a high level of a heart stress marker called NT-proBNP (over 125 pg/mL) or BNP (35 pg/mL or higher).
- You are a new user of Jardiance or certain other heart failure medications, meaning you haven't taken them in the past 6 months.
- You have not taken any SGLT2 inhibitor (a class of diabetes and heart failure drugs) in the past 6 months.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether Jia Shen tablets, a traditional Chinese medicine, can help people with chronic heart failure due to coronary heart disease. It aims to improve symptoms and quality of life.
This trial tests a Chinese herbal tablet, Jia Shen, to see how the body processes it and if it helps people with chronic heart failure. It is for adults with weak heart pumping and stable medication use.
This study looks at how well Jardiance works and its safety in Chinese patients with a type of heart failure where the heart pumps normally but doesn't fill properly. It aims to see if this medicine helps these patients feel better and stay out of the hospital.
This study tests a medicine called Jardiance (an SGLT2 inhibitor) to see if it helps improve heart function in adults with congenital heart disease who have recently experienced a drop in their heart pumping ability. Participants will take the medication alongside standard heart failure treatments.
This study tests whether continuing empagliflozin (a heart failure medicine) during a hospital stay for heart failure is beneficial compared to stopping it. Participation may help improve recovery and reduce complications.
This trial tests if dapagliflozin, a medication usually used for diabetes, can help people with acute heart failure recover heart function. If you are in the hospital for heart failure, this study will check if the drug improves how your heart squeezes.
Hear when a new Heart Failure of Reduced Ejection Fraction (HFrEF) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.